A	a	O	O	O	O
pyridoxine-dependent	pyridoxine-dependent	O	O	O	O
behavioral	behavioral	O	O	OTHERS	I
disorder	disorder	O	O	OTHERS	I
unmasked	unmasked	O	O	O	O
by	by	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
3-year-old	3-year-old	O	O	O	O
girl	girl	O	O	O	O
had	had	O	O	O	O
behavioral	behavioral	O	O	OTHERS	I
deterioration	deterioration	O	O	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
hyperkinesis	hyperkinesis	O	O	OTHERS	I
,	,	O	O	O	O
irritability	irritability	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
sleeping	sleeping	O	O	OTHERS	I
difficulties	difficulties	O	O	OTHERS	I
after	after	O	O	O	O
the	the	O	O	O	O
therapeutic	therapeutic	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
pharmacologic	pharmacologic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
pyridoxine	pyridoxine	CHEMICALS	O	OTHERS	I
hydrochloride	hydrochloride	O	O	OTHERS	I
led	led	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
disappearance	disappearance	O	O	O	O
of	of	O	O	O	O
symptoms	symptoms	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
discontinuing	discontinuing	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
a	a	O	O	O	O
similar	similar	O	O	O	O
pattern	pattern	O	O	O	O
of	of	O	O	O	O
behavior	behavior	O	O	O	O
was	was	O	O	O	O
noted	noted	O	O	O	O
that	that	O	O	O	O
was	was	O	O	O	O
controlled	controlled	O	O	O	O
by	by	O	O	O	O
pyridoxine	pyridoxine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
placebo	placebo	O	O	O	O
had	had	O	O	O	O
no	no	O	O	O	O
effect	effect	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
niacinamide	niacinamide	O	O	OTHERS	I
was	was	O	O	O	O
as	as	O	O	O	O
effective	effective	O	O	O	O
as	as	O	O	O	O
pyridoxine	pyridoxine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Periodic	periodic	O	O	O	O
withdrawal	withdrawal	O	O	O	O
of	of	O	O	O	O
pyridoxine	pyridoxine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
return	return	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hyperkinesis	hyperkinesis	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
pyridoxal	pyridoxal	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
blood	blood	O	O	O	O
was	was	O	O	O	O
normal	normal	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
periods	periods	O	O	O	O
of	of	O	O	O	O
relapse	relapse	O	O	O	O
.	.	O	O	O	O

Metabolic	metabolic	O	O	O	O
studies	studies	O	O	O	O
suggested	suggested	O	O	O	O
a	a	O	O	O	O
block	block	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
kynurenine	kynurenine	O	O	OTHERS	I
pathway	pathway	O	O	O	O
of	of	O	O	O	O
tryptophan	tryptophan	O	O	OTHERS	I
metabolism	metabolism	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
followed	followed	O	O	O	O
for	for	O	O	O	O
six	six	O	O	O	O
years	years	O	O	O	O
and	and	O	O	O	O
has	has	O	O	O	O
required	required	O	O	O	O
pharmacologic	pharmacologic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
pyridoxine	pyridoxine	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
control	control	O	O	O	O
her	her	O	O	O	O
behavior	behavior	O	O	O	O
.	.	O	O	O	O

